Mutations in MAP3K1 that cause 46,XY disorders of sex development disrupt distinct structural domains in the protein.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
15 05 2019
Historique:
received: 23 10 2018
revised: 19 12 2018
accepted: 31 12 2018
pubmed: 5 1 2019
medline: 8 2 2020
entrez: 5 1 2019
Statut: ppublish

Résumé

Missense mutations in the gene, MAP3K1, are a common cause of 46,XY gonadal dysgenesis, accounting for 15-20% of cases [Ostrer, 2014, Disorders of sex development (DSDs): an update. J. Clin. Endocrinol. Metab., 99, 1503-1509]. Functional studies demonstrated that all of these mutations cause a protein gain-of-function that alters co-factor binding and increases phosphorylation of the downstream MAP kinase pathway targets, MAPK11, MAP3K and MAPK1. This dysregulation of the MAP kinase pathway results in increased CTNNB1, increased expression of WNT4 and FOXL2 and decreased expression of SRY and SOX9. Unique and recurrent pathogenic mutations cluster in three semi-contiguous domains outside the kinase region of the protein, a newly identified N-terminal domain that shares homology with the Guanine Exchange Factor (residues Met164 to Glu231), a Plant HomeoDomain (residues Met442 to Trp495) and an ARMadillo repeat domain (residues Met566 to Glu862). Despite the presence of the mutation clusters and clinical data, there exists a dearth of mechanistic insights behind the development imbalance. In this paper, we use structural modeling and functional data of these mutations to understand alterations of the MAP3K1 protein and the effects on protein folding, binding and downstream target phosphorylation. We show that these mutations have differential effects on protein binding depending on the domains in which they occur. These mutations increase the binding of the RHOA, MAP3K4 and FRAT1 proteins and generally decrease the binding of RAC1. Thus, pathologies in MAP3K1 disrupt the balance between the pro-kinase activities of the RHOA and MAP3K4 binding partners and the inhibitory activity of RAC1.

Identifiants

pubmed: 30608580
pii: 5272619
doi: 10.1093/hmg/ddz002
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Armadillo Domain Proteins 0
FRAT1 protein, human 0
Forkhead Box Protein L2 0
Proto-Oncogene Proteins 0
RAC1 protein, human 0
Sex-Determining Region Y Protein 0
RHOA protein, human 124671-05-2
MAP Kinase Kinase Kinase 1 EC 2.7.11.25
MAP Kinase Kinase Kinase 4 EC 2.7.11.25
MAP3K1 protein, human EC 2.7.11.25
MAP3K4 protein, human EC 2.7.11.25
rac1 GTP-Binding Protein EC 3.6.5.2
rhoA GTP-Binding Protein EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1620-1628

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Adam Chamberlin (A)

Ambry Genetics, Aliso Viejo, CA, USA.

Robert Huether (R)

Ambry Genetics, Aliso Viejo, CA, USA.

Aline Z Machado (AZ)

Division of Endocrinology, Hormone and Molecular Genetics Laboratory (LIM), Hospital das Clinicas, University of Sao Paulo Medical School, Avenida Dr. Eneas de C Aguiar, andar Bloco, São Paulo, SP, Brazil.

Michael Groden (M)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.

Hsiao-Mei Liu (HM)

Ambry Genetics, Aliso Viejo, CA, USA.

Kinnari Upadhyay (K)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.

Vivian O (V)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.

Nathalia L Gomes (NL)

Division of Endocrinology, Hormone and Molecular Genetics Laboratory (LIM), Hospital das Clinicas, University of Sao Paulo Medical School, Avenida Dr. Eneas de C Aguiar, andar Bloco, São Paulo, SP, Brazil.

Antonio M Lerario (AM)

Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

Mirian Y Nishi (MY)

Division of Endocrinology, Hormone and Molecular Genetics Laboratory (LIM), Hospital das Clinicas, University of Sao Paulo Medical School, Avenida Dr. Eneas de C Aguiar, andar Bloco, São Paulo, SP, Brazil.

Elaine M F Costa (EMF)

Division of Endocrinology, Hormone and Molecular Genetics Laboratory (LIM), Hospital das Clinicas, University of Sao Paulo Medical School, Avenida Dr. Eneas de C Aguiar, andar Bloco, São Paulo, SP, Brazil.

Berenice Mendonca (B)

Division of Endocrinology, Hormone and Molecular Genetics Laboratory (LIM), Hospital das Clinicas, University of Sao Paulo Medical School, Avenida Dr. Eneas de C Aguiar, andar Bloco, São Paulo, SP, Brazil.

Sorahia Domenice (S)

Division of Endocrinology, Hormone and Molecular Genetics Laboratory (LIM), Hospital das Clinicas, University of Sao Paulo Medical School, Avenida Dr. Eneas de C Aguiar, andar Bloco, São Paulo, SP, Brazil.

Jacqueline Velasco (J)

Pediatric Endocrinology, Marshfield Clinic, Marshfield, WI, USA.

Johnny Loke (J)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.

Harry Ostrer (H)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH